Drug intelligence / Profile preview

TALA-711

Development stage: Preclinical
Lead developer: Talawar Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

TALA-711 is a preclinical-stage bispecific antibody being developed by Talawar Therapeutics for the treatment of immunologic diseases. It is designed to simultaneously target Interleukin-13 (IL-13) and a second, undisclosed target. By inhibiting IL-13, a key cytokine involved in Type 2 inflammation, alongside another pathway, TALA-711 aims to provide enhanced therapeutic efficacy in inflammatory and autoimmune conditions where IL-13 plays a central role in pathogenesis, such as asthma or atopic dermatitis.

Targets

IL-13 (Interleukin-13)

Beyond the preview

Go deeper on TALA-711.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TALA-711.

Explore the full profile